Use of GLP-1 medicines for weight loss has spread to 8.5% of households in Great Britain, according to Worldpanel by Numerator data reported Thursday, as new pill options and a growing number of male users accompanied a sharp rise in uptake.
The household share rose from 6.3% in February to 8.5% in August 2026, while about 2.6 million adults were taking weight-loss medication in August, roughly 700,000 more than in February, The Guardian reported, citing a Worldpanel survey of more than 9,600 households. Reuters reported the survey sample as 9,629 households.
Men represented 32% of users in August, compared with 23% in February, and their reported number rose from 440,000 to 830,000. Pills accounted for 11.2% of GLP-1 users in August, according to Worldpanel figures reported by Reuters.
The U.K. medicines regulator authorized oral GLP-1 medicines during 2026. The Medicines and Healthcare products Regulatory Agency said it authorized orforglipron for weight management and Type 2 diabetes on Aug. 10, making Britain the first country in Europe to approve the tablet.
The increase is also coinciding with changes in grocery spending. Worldpanel estimated that households with a GLP-1 user spent £1 billion less on groceries than expected in the year after treatment began, or £389 per household annually, according to Reuters and The Grocer. The analysis also found 415 million fewer grocery items purchased.
Nishita Pattni, a senior consultant at Worldpanel by Numerator, told The Grocer that the increase from February to August approached the gain recorded over the preceding year. Worldpanel forecast that use could exceed 10% of Great Britain households in 2027.



